Moderna (MRNA) Other Non-Current Assets (2017 - 2026)

Moderna (MRNA) has 10 years of Other Non-Current Assets data on file, last reported at $675.0 million in Q1 2026.

• On a quarterly basis, Other Non-Current Assets rose 21.4% year-over-year to $675.0 million in Q1 2026; TTM through Mar 2026 was $675.0 million, a 21.4% increase from a year earlier, with the FY2025 full-year figure at $605.0 million, up 1.85% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $675.0 million, up from $605.0 million in the prior quarter.
• Over the last five years, Other Non-Current Assets for MRNA reached as high as $1.3 billion in Q2 2023 and fell as low as $12.0 million in Q1 2022.
• Historically, Other Non-Current Assets has averaged $607.2 million across 5 years, with a median of $605.0 million in 2025.
• Across the five-year window, Other Non-Current Assets jumped 9600.0% in 2023 and slumped 50.31% in 2024, its largest moves.
• Year by year, Other Non-Current Assets stood at $988.0 million in 2022, then slipped by 22.47% to $766.0 million in 2023, then dropped by 22.45% to $594.0 million in 2024, then grew by 1.85% to $605.0 million in 2025, then gained by 11.57% to $675.0 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Assets figures were $675.0 million in Q1 2026, $605.0 million in Q4 2025, and $530.0 million in Q3 2025.